There’s an App for That: University of Michigan Releases Skin Cancer Self-Audit App

Jeannette Y. Wick, RPh, MBA, FASCP
Published Online: Thursday, September 27, 2012
Follow Pharmacy_Times:
The app for iPhone and iPad allows users to use whole body photography to track moles that may develop into melanoma.

The University of Michigan has released a new app for iPhone and iPad to help patients track moles that may develop into melanoma. The app was developed to make whole body photography—an important but underutilized tool to track melanoma—easier.
Users can download the app, called UMSKinCheck, from the iTunes store for free. The app first prompts users to set a reminder to take a new set of photos in the next 30 and 90 days. Next, the app directs users to take photos from 23 different positions. The directions are very specific, and a friend or family member is needed to take the photos. These photos are stored as a baseline and can be compared to future photos.
The app also provides information about melanoma. One section includes pictures demonstrating the ABCDs of melanoma (Asymmetry, Border, Color, and Difference). Another section shows photos of common skin lesions. A third section offers helpful sun safety tips. (Eg, “If your shadow appears shorter than you are, seek shade.”)
Another tool allows users to calculate their risk by entering personal information and history, such as geographic region, sex, race, age, complexion, number and size of moles, back freckling, etc. For example, changing gender information from female to male (and keeping other factors constant) added a question about history of blistering sunburns. As it’s configured now, this tool can only calculate risk for non-Hispanic whites.

Ms. Wick is a visiting professor at the University of Connecticut School of Pharmacy and a freelance writer from Virginia.

Related Articles
Since patients with Barrett’s esophagus seem to progress to cancerous stages faster than others, health care professionals might perceive that controlling acid reflux would prevent the transition.
The FDA announced today that it has expanded the indication of Bristol-Myers Squibb’s anticancer medication nivolumab (Opdivo) to include the treatment of patients with metastatic squamous non-small cell lung cancer with progression on or after platinum-based chemotherapy.
Celgene today announced that the FDA has granted an expanded use approval for its multiple myeloma drug, lenalidomide (Revlimid).
Although testosterone is often considered to be a catalyst of prostate cancer, a recent study suggests that the hormone may be able to subdue advanced prostate cancer and break down resistance to testosterone-blocking drugs used to treat the disease.
Latest Issues
  • photo
    Pharmacy Times
    Health-System Edition
    Directions in Pharmacy
    OTC Guide
    Generic Supplements
  • photo
    Pharmacy Careers
    Specialty Pharmacy Times